In general, through network pharmacology and in vivo and in vitro experiments, it was found that intervention with PRPM and its main compound emodin could improve lipid droplet accumulation in NAFLD model mice and a fatty liver cell model, and its mechanism may be related to the inhibition of p38/phosphorylated p38. The gene discussed is MAPK1; the disease is metabolic dysfunction-associated steatotic liver disease.